After a 20% fall in share price following the recent guidance downgrade, Citi now feels there is enough risk priced in to the stock and as such has lifted its recommendation to Buy.
Saying that, the analysts do still highlight the belief that pathology volumes need to recover, that there is funding risk in other countries and that acquisition discipline will be critical. Sector: Health Care Equipment & Services.
Target price is $12.28.Current Price is $10.07. Difference: $2.21 – (brackets indicate current price is over target). If SHL meets the Citi target it will return approximately 18% (excluding dividends, fees and charges – negative figures indicate an expected loss).